JP2008501632A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008501632A5 JP2008501632A5 JP2006552676A JP2006552676A JP2008501632A5 JP 2008501632 A5 JP2008501632 A5 JP 2008501632A5 JP 2006552676 A JP2006552676 A JP 2006552676A JP 2006552676 A JP2006552676 A JP 2006552676A JP 2008501632 A5 JP2008501632 A5 JP 2008501632A5
- Authority
- JP
- Japan
- Prior art keywords
- galr2
- brain
- specific agonist
- injury
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100036584 Galanin receptor type 2 Human genes 0.000 claims description 54
- 101001072780 Homo sapiens Galanin receptor type 2 Proteins 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 34
- 239000000556 agonist Substances 0.000 claims description 28
- 208000029028 brain injury Diseases 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 14
- 208000014644 Brain disease Diseases 0.000 claims description 12
- 230000006931 brain damage Effects 0.000 claims description 11
- 231100000874 brain damage Toxicity 0.000 claims description 11
- 230000002265 prevention Effects 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims 16
- 208000014674 injury Diseases 0.000 claims 9
- 208000027418 Wounds and injury Diseases 0.000 claims 6
- 210000004556 brain Anatomy 0.000 claims 6
- 230000001900 immune effect Effects 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 238000001356 surgical procedure Methods 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- 102100028447 Galanin receptor type 1 Human genes 0.000 claims 4
- 102100036588 Galanin receptor type 3 Human genes 0.000 claims 4
- 101001061554 Homo sapiens Galanin receptor type 1 Proteins 0.000 claims 4
- 101001072777 Homo sapiens Galanin receptor type 3 Proteins 0.000 claims 4
- 208000035143 Bacterial infection Diseases 0.000 claims 3
- 208000018380 Chemical injury Diseases 0.000 claims 3
- 206010014498 Embolic stroke Diseases 0.000 claims 3
- 101800002068 Galanin Proteins 0.000 claims 3
- 102400001370 Galanin Human genes 0.000 claims 3
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims 3
- 101100447612 Homo sapiens GALR2 gene Proteins 0.000 claims 3
- 206010043647 Thrombotic Stroke Diseases 0.000 claims 3
- 208000036142 Viral infection Diseases 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000001580 bacterial effect Effects 0.000 claims 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims 3
- 230000002612 cardiopulmonary effect Effects 0.000 claims 3
- 238000000502 dialysis Methods 0.000 claims 3
- 230000003073 embolic effect Effects 0.000 claims 3
- 108010014357 galanin (2-11)-amide Proteins 0.000 claims 3
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 3
- 230000000302 ischemic effect Effects 0.000 claims 3
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 claims 3
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 230000010410 reperfusion Effects 0.000 claims 3
- 210000000278 spinal cord Anatomy 0.000 claims 3
- 230000008733 trauma Effects 0.000 claims 3
- 230000009385 viral infection Effects 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 210000002569 neuron Anatomy 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 101100447613 Mus musculus Galr2 gene Proteins 0.000 claims 1
- 101100447614 Rattus norvegicus Galr2 gene Proteins 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 108700010039 chimeric receptor Proteins 0.000 claims 1
- 210000003618 cortical neuron Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000012188 high-throughput screening assay Methods 0.000 claims 1
- 230000000971 hippocampal effect Effects 0.000 claims 1
- 210000004295 hippocampal neuron Anatomy 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0403509.3A GB0403509D0 (en) | 2004-02-17 | 2004-02-17 | Galanin receptors and brain injury |
| PCT/GB2005/000188 WO2005080427A1 (en) | 2004-02-17 | 2005-01-18 | Galanin receptors and brain injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008501632A JP2008501632A (ja) | 2008-01-24 |
| JP2008501632A5 true JP2008501632A5 (enExample) | 2008-03-06 |
Family
ID=32039889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006552676A Pending JP2008501632A (ja) | 2004-02-17 | 2005-01-18 | ガラニン受容体および脳障害 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20080020975A1 (enExample) |
| EP (1) | EP1723175A1 (enExample) |
| JP (1) | JP2008501632A (enExample) |
| CN (1) | CN1922205A (enExample) |
| AU (1) | AU2005214115B2 (enExample) |
| CA (1) | CA2555550A1 (enExample) |
| GB (1) | GB0403509D0 (enExample) |
| WO (1) | WO2005080427A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1809619A1 (en) | 2004-10-21 | 2007-07-25 | Transtech Pharma, Inc. | Bissulfonamide compounds as agonists of galr1, compositions, and methods of use |
| GB0523550D0 (en) | 2005-11-18 | 2005-12-28 | Hunter Fleming Ltd | Therapeutic uses of steroidal compounds |
| AU2008207287A1 (en) * | 2007-01-19 | 2008-07-24 | Howard Florey Institute Of Experimental Physiology And Medicine | Use of galanin in a method of treating neurodegenerative diseases or conditions |
| WO2009079078A1 (en) | 2007-12-14 | 2009-06-25 | Labogroup S.A.S. | Delivering aerosolizable food products |
| CN108404115A (zh) | 2010-10-15 | 2018-08-17 | 纽约市哥伦比亚大学理事会 | 肥胖症-相关的基因和它们的蛋白和其用途 |
| EP2821081A1 (en) * | 2013-07-05 | 2015-01-07 | ResuSciTec GmbH | Protective solution for preventing or reducing reperfusion injury of the brain and the whole body |
| KR101514440B1 (ko) * | 2013-12-13 | 2015-04-22 | 고려대학교 산학협력단 | 갈라닌 수용체 3형의 리간드로서 스펙신의 용도 |
| US10314911B2 (en) * | 2014-04-08 | 2019-06-11 | Healthpartners Research & Education | Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin |
| KR101885238B1 (ko) * | 2015-11-30 | 2018-08-06 | 주식회사 뉴라클사이언스 | 스펙신 기반 갈라닌 ２형 수용체의 효현제 및 이의 용도 |
| CN106880837A (zh) * | 2015-12-15 | 2017-06-23 | 北京脑重大疾病研究院 | 一种甘丙肽在制备防止缺血性脑卒的试剂中的应用 |
| ES2707210B2 (es) * | 2017-10-02 | 2020-09-30 | Univ Malaga | GAL(1-15) y análogos de la misma para uso en la prevención y/o tratamiento de trastornos y efectos relacionados con el alcohol. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2216227A1 (en) * | 1996-01-24 | 1997-07-31 | Synaptic Pharmaceutical Corporation | Dna encoding galanin galr2 receptors and uses thereof |
| US5972624A (en) * | 1996-01-24 | 1999-10-26 | Synaptic Pharmaceutical Corporation | Method of identifying ligands which bind recombinant galanin receptor (GALR2) |
| EP0918455B1 (en) * | 1996-07-24 | 2003-04-16 | Neurotargets Limited | Use of galanin to repair nerve damage |
| WO1998029440A1 (en) * | 1996-12-27 | 1998-07-09 | Merck & Co., Inc. | Mouse galanin receptor galr2 and nucleotides encoding same |
| US6337206B1 (en) * | 1997-12-18 | 2002-01-08 | Merck & Co., Inc. | Nucleic acid encoding mouse galanin receptor (GALR2) |
| WO2002096934A1 (en) * | 2001-05-25 | 2002-12-05 | Kemia, Inc. | Non-natural galanin receptor ligands |
-
2004
- 2004-02-17 GB GBGB0403509.3A patent/GB0403509D0/en not_active Ceased
-
2005
- 2005-01-18 EP EP05701953A patent/EP1723175A1/en not_active Ceased
- 2005-01-18 CA CA002555550A patent/CA2555550A1/en not_active Abandoned
- 2005-01-18 JP JP2006552676A patent/JP2008501632A/ja active Pending
- 2005-01-18 AU AU2005214115A patent/AU2005214115B2/en not_active Ceased
- 2005-01-18 WO PCT/GB2005/000188 patent/WO2005080427A1/en not_active Ceased
- 2005-01-18 CN CNA2005800051943A patent/CN1922205A/zh active Pending
- 2005-01-18 US US10/589,533 patent/US20080020975A1/en not_active Abandoned
-
2009
- 2009-10-27 US US12/606,439 patent/US20100184638A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3273792B2 (ja) | Ｎｍｄａレセプターのアロステリックモジュレーター | |
| US11254720B2 (en) | Methods and systems for designing and/or characterizing soluble lipidated ligand agents | |
| CN101237870B (zh) | 伴随的药物试剂及其用途 | |
| JP2020023551A (ja) | 高コレステロール血症、アテローム性動脈硬化症、冠動脈性心疾患、胆石、肥満症、および他の心血管疾患の処置のために有用なグアニル酸シクラーゼのアゴニスト | |
| EP3777863A1 (en) | Cenicriviroc combination therapy for the treatment of fibrosis | |
| JP2008501632A5 (enExample) | ||
| JP2011528375A (ja) | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト | |
| KR20110104024A (ko) | 키나아제의 세포-침투성 펩티드-기초된 저해물질 | |
| JP2011522828A (ja) | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト | |
| JP2005537245A5 (ja) | プロテイナーゼ活性化レセプターのアンタゴニストを含む組成物および方法 | |
| JP6640725B2 (ja) | ｓｐａｄｉｎのレトロ−インベルソ類似体は増大された抗うつ作用を示す | |
| CA2671470A1 (en) | Powder formulation for valganciclovir | |
| JP2006506942A5 (enExample) | ||
| JP2009537563A5 (enExample) | ||
| JP6175054B2 (ja) | ヒストンアセチルトランスフェラーゼ活性剤の使用 | |
| CN101657453A (zh) | 作为PKC-θ抑制剂的嘌呤类 | |
| TW201806596A (zh) | 抗病毒劑 | |
| JP2009545526A5 (enExample) | ||
| CN115335395A (zh) | Gip受体激动剂肽化合物的qd给药及其用途 | |
| TW200831530A (en) | Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity | |
| AU2005231822B2 (en) | Methods of reducing aggregation of IL-1ra | |
| Gaudilliere et al. | To market, to market—2000 | |
| EP3119388B1 (en) | Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders | |
| JP2003528144A5 (enExample) | ||
| JP2021522271A (ja) | 虚弱および加齢を改善するための方法 |